ESTRO 2024 - Abstract Book

S1806

Clinical - Lung

ESTRO 2024

A statistically significant correlation was noted between the Dmean received by the esophagus and the occurrence of dysphagia after the completion of radiotherapy (p= 0.04). Moreover, chemotherapy significantly increased the risk of esophagitis (p=0.05), while oral steroid medication reduced it.

Conclusion:

As our study showed, the factors correlated with the occurrence of dysphagia after hypofractionated palliative lung radiotherapy were the Dmean in the esophagus and chemotherapy treatment. In the absence of specific constraints for the esophagus in the case of hypofractionated treatment, and considering the significant impact of dysphagia on the prognosis and quality of life of patients, we suggest considering a Dmean of 9 Gy as a dosimetric constraint. However, prospective studies are necessary to confirm these findings.

Keywords: Palliative, hypofractionated, dysphagia

3080

Digital Poster

Clinical outcomes following stereotactic ablative body radiotherapy to central lung tumours

Julie Duong, Riya Patel, Prasana Nariyangadu, Karen Venables, Anup Vinayan, Mark Harrison, Peter Ostler, Nihal Shah, Yat Tsang, Suraiya Dubash

Mount Vernon Cancer Centre, Oncology, London, United Kingdom

Purpose/Objective:

The safety and effectiveness of using stereotactic ablative body radiotherapy (SABR) for central lung tumours is associated with increased toxicity. We present our centres experience and clinical outcomes.

Material/Methods:

The study encompasses patients diagnosed with both primary and oligometastatic central lung tumours, specifically those positioned within 2 cm of the proximal bronchial tree, mediastinal and pericardial pleura, as well as the brachial plexus. This retrospective analysis includes all patients treated with a specialized robotic stereotactic RT machine from May 2016 till July 2023. The treatment protocol employed consisted of administering 50 Gray in 5 fractions, which were delivered on consecutive days propelled by image-guided RT under autonomous breathing, all while under the meticulous surveillance of real-time motion tracking. An integral component of this study is the scrutiny of the maximum dose absorbed by the trachea & bronchus. Follow-ups were systematically arranged 6 weeks post-treatment, semi-annually for the subsequent two years, and annually for years 3 through 5. Furthermore, the overall survival (OS) rate was computed using Kaplan-Meier methodology, and post-radiotherapy toxicity data was classified following the CTCAE v4.0 protocol.